IRCT2017062734782N1 IRCT 2017-09-09 Isfahan University of Medical Sciences The efficacy of nasal high frequency ventilation in treatment of neonatal respiratory syndrome Therapeutic effect of Nasal high frequency ventilation(NHFV) versus nasal continuous positive airway pressure(NCPAP) for respiratory distress syndrome in newborn with birth with more than 1000 gram and more than 30 week of gestational age 2017-10-22 anticipated 62 Complete https://irct.ir/trial/26488 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. N/A Respiratory distress syndrome. Intervention 1: Infants with respiratory distress syndrome according of inclusion criteria randomized to NCPAP (control group) will treat with nasal CPAP shortly after birth. CPAP pressure will consider as 6-7 cmH20 and FIO2 adjust to maintain o2 saturation of patients between 89-95%. Surfactant (200mg/kg first dose and then 100mg/kg the next doses, curosurf (Chiesa pharmaceuticals, Parma, Italy) will administrate if patients need FIo2 > 35% to keep desired SPO2. If FIO2 reach to under 30% patient wean to Humidified High Flow Nasal Cannula (HHFNC) and when FIO2 reach to 21% and respiratory distress improved, HHFNC also will discontinued. Surfactant administrate as INSURE method. NCPAP failure defined as apnea or PH<7.2 and Pco2 >60 mmHg. Intervention 2: Infants with respiratory distress syndrome according of inclusion criteria randomized to NHFV (control group) will treat with nasal high frequency ventilator [Fabian, Acutronic Medical Systems AG, based in Hirzel (Zurich, Switzerland)], shortly after birth. Pmean pressure will consider as 8 cmH20 and FIO2 adjust to maintain O2 saturation of patients between 89-95%. Initial frequency will set as 10 Hz. Amplitude will set based the vibration of upper chest wall and the neck of patients and increased to maximum 20mmHg. Surfactant (200mg/kg first dose and then 100mg/kg the next doses, curosurf (Chiesa pharmaceuticals, Parma, Italy) will administrate if patients need FIo2 > 35% to keep desired SPO2. If FIO2 reach to under 30% patient wean to Humidified High Flow Nasal Cannula (HHFNC) and when FIO2 reach to 21% and respiratory distress improved, HHFNC also will discontinued. Surfactant administrate as INSURE method. NCPAP failure defined as apnea or PH<7.2 and Pco2 >60 mmHg.